Science Explorer Interactive view Map
Topic · Oncology

Cancer Immunotherapy and Biomarkers

Cancer Immunotherapy and Biomarkers is a research topic within Oncology. Science Explorer counts 62k research works in it since 1951. 22.6% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting.

  • Immune Checkpoint Blockade
  • PD-1 and PD-L1
  • Tumor Microenvironment
  • Tumor Mutational Burden
  • Immune-related Adverse Events
  • T-cell Exhaustion
  • Neoantigens
  • Biomarkers for Immunotherapy
  • Combination Therapies
  • Cancer Immunoediting
Research works
62k
fractional, since 1951
In the world top 10%
14k
per year above
Top-10% rate
22.6%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+184%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Cancer Immunotherapy and Biomarkers research?

By volume, China and the United States publish the most (7.8k and 5.8k works in 2022–2025).

By volume, 2022–2025

  1. 1 China 7.8k works
  2. 2 United States 5.8k works
  3. 3 Japan 1.4k works
  4. 4 Germany 842 works
  5. 5 Italy 789 works
  6. 6 France 717 works
  7. 7 United Kingdom 654 works
  8. 8 South Korea 528 works
  9. 9 Spain 519 works
  10. 10 India 401 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 39.9%United States: 30.1%Japan: 7.0%Germany: 4.3%6 others listed: 18.6%40%largest
China7,752 · 39.9%United States5,848 · 30.1%Japan1,359 · 7.0%Germany842 · 4.3%6 others listed3,609 · 18.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cancer Immunotherapy and Biomarkers research?

By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer Immunotherapy and Biomarkers research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sun Yat-sen University.

By volume, 2022–2025

  1. 1 The University of Texas MD Anderson Cancer CenterUnited States 260 works
  2. 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 200 works
  3. 3 Sun Yat-sen UniversityChina 184 works
  4. 4 Sichuan UniversityChina 121 works
  5. 5 Memorial Sloan Kettering Cancer CenterUnited States 111 works
  6. 6 Nanjing Medical UniversityChina 96 works
  7. 7 Shanghai Jiao Tong UniversityChina 93 works
  8. 8 Peking UniversityChina 93 works
  9. 9 Dana-Farber Cancer InstituteUnited States 91 works
  10. 10 Central South UniversityChina 88 works

Who are the leading researchers in Cancer Immunotherapy and Biomarkers?

The most-cited researchers publishing on Cancer Immunotherapy and Biomarkers include Kenneth J. Livak, Y. Wu and Gad Getz.

  1. 1 Kenneth J. Livak United States 20k citations
  2. 2 Y. Wu China 7k citations
  3. 3 Gad Getz United States 6.2k citations
  4. 4 Lawrence H. Schwartz United States 5.8k citations
  5. 5 Matthias Mann Germany 5.1k citations
  6. 6 Ahmedin Jemal United States 4.9k citations
  7. 7 Dirk Schadendorf Germany 4.4k citations
  8. 8 Charles M. Perou United States 4.2k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Cancer Immunotherapy and Biomarkers research done?

The largest centres of Cancer Immunotherapy and Biomarkers research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Amsterdam, Plainview and Lancaster.

Largest cities, 2022–2025

  1. 1 Beijing China 887 works
  2. 2 Shanghai China 752 works
  3. 3 Guangzhou China 722 works
  4. 4 New York United States 386 works
  5. 5 Houston United States 353 works
  6. 6 Nanjing China 348 works
  7. 7 Hangzhou China 324 works
  8. 8 Seoul South Korea 306 works
  9. 9 Chengdu China 306 works
  10. 10 Boston United States 298 works

Where it is the local speciality

  1. AmsterdamNL · 32.7 works32×
  2. PlainviewUS · 42.6 works24×
  3. LancasterUS · 38.7 works22×
  4. RahwayUS · 40.9 works21×
  5. KashiwaJP · 39.1 works19×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Cancer Immunotherapy and Biomarkers than the world average.

See Cancer Immunotherapy and Biomarkers on the map

Where is the best place to study Cancer Immunotherapy and Biomarkers?

Among universities, judged by research, Oncode Institute, Chinese Academy of Medical Sciences & Peking Union Medical College and China Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 31.39%fractional works in this node (log) →share in the world top 10% →Oncode Institute: 23, 45.6%Chinese Academy of Medical Sciences & Peking Union Medical College: 200, 28.0%China Medical University: 63, 40.5%Shanghai Medical College of Fudan University: 30, 34.5%Nanjing Medical University: 96, 29.2%Shandong First Medical University: 82, 23.4%Southern Medical University: 68, 30.0%Fujian Medical University: 79, 22.6%Sun Yat-sen University: 184, 31.5%Institute of Cancer Research: 14, 28.6%Oncode InstituteChina Medical Univer…Shanghai Medical Col…Chinese Academy of M…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Oncode InstituteNetherlands 79.245.6%34.9×23 +474.4%
2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 76.028.0%9.2×200 +562.9%
3 China Medical UniversityChina 73.440.5%8.8×63 +176.1%
4 Shanghai Medical College of Fudan UniversityChina 70.334.5%17.0×30 +380.7%
5 Nanjing Medical UniversityChina 69.529.2%8.4×96 +242.2%
6 Shandong First Medical UniversityChina 68.723.4%14.2×82 +741.5%
7 Southern Medical UniversityChina 68.330.0%8.5×68 +283.4%
8 Fujian Medical UniversityChina 67.822.6%10.1×79 +619.6%
9 Sun Yat-sen UniversityChina 67.431.5%5.1×184 +251.7%
10 Institute of Cancer ResearchUnited Kingdom 65.528.6%20.3×14 +480.6%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Cancer Immunotherapy and Biomarkers research growing?

Output in 2018–2022 was 184% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Cancer Immunotherapy and Biomarkers.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.